IR
Cellid Co.,Ltd. leads research of anti-cancer immunotherapies and Vaccines for preventing infectious diseases
Disclosure
Total of 10posts
| Number | Title | Person with Duty to Submit | Receipt Date |
|---|---|---|---|
| 10 | Designation as Investment Alert Issue | 2026-07-29 | |
| 9 | Advance notice for assignment of issue for abnormal rise | 2026-07-28 | |
| 8 | Decision on Provision of Collateral for Others | 2026-07-07 | |
| 7 | Material Management Information related to Judgment of Investment(Study Results)(COVID-19 예방 백신 AdCLD-CoV19-1 OMI의 제3상 임상시험 결과) | 2026-06-26 | |
| 6 | [Revised]Material Management Information related to Judgment of Investment(사업반환청구의 소 제기의 건) | 2026-06-25 | |
| 5 | Outcomes of Extraordinary General Meeting of Shareholders | 2026-05-22 | |
| 4 | Material Management Information related to Judgment of Investment(COVID-19 예방 백신 AdCLD-CoV19-1 LP.8.1의 제2상 임상시험 계획 승인(IND) 신청 반려) | 2026-05-08 | |
| 3 | [Revised]New Facilities Investment, etc. | 2026-04-30 | |
| 2 | [Revised]Resolutions for Convocation of General Meeting of Shareholders(임시주주총회) | 2026-04-30 | |
| 1 | Extension of overheated short-selling issue designation (subject to extension of restriction on short-selling) | KOSDAQ STOCK MKT. | 2026-04-22 |
